Tc Biopharm (holdings) PLC F-1 registration statements
The S-1’s counterpart for foreign private issuers registering shares for sale in the United States.
TC BioPharm aims to increase its public offering by $2 million through a new registration statement.
TC BioPharm is launching a public offering of American Depositary Shares (ADSs) and warrants to raise capital for its clinical development programs.
TC BioPharm is launching a public offering of American Depositary Shares (ADSs) and warrants to raise capital for its clinical-stage immunotherapy programs.
TC BioPharm is offering American Depositary Shares (ADSs) and warrants in a combined offering to raise capital for clinical trials and operating expenses.
TC BioPharm is offering up to 6,297,230 American Depositary Shares (ADSs) and warrants in a bid to raise approximately $5 million for clinical trials and working capital.